This thesis delves into the exploration of Antibody Drug Conjugates (ADCs) in cancer therapy, tracing their evolution from conception to the present day. Throughout the years, researchers and drug developers have made significant strides in enhancing the effectiveness of this potent weapon against cancer. By deepening their pharmacological understanding and fine-tuning the constituents of ADCs, they have achieved higher efficacy while minimizing undesirable side effects. The thesis highlights the remarkable progress made in this field and underscores the immense potential of ADCs as a targeted and promising approach in the fight against cancer.